EDMONTON, ALBERTA--(MARKET WIRE)--Jun 8, 2007 -- ViRexx Medical Corp. (Toronto:VIR.TO - News) (AMEX:REX - News), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced the results from a Phase II trial of OvaRex® MAb conducted by ViRexx’s licensing partner, Unither Pharmaceuticals, Inc. (Unither), a subsidiary of United Therapeutics Corporation. Patients with newly diagnosed advanced ovarian cancer were treated by surgery and then by front-line chemotherapy in combination with OvaRex® MAb. The results were presented at the American Society of Clinical Oncology (ASCO) annual meeting. The trial demonstrated that cellular and humoral (antibody) immune responses to OvaRex® MAb treatment were preserved and in fact enhanced when administered with front-line treatment.
